



COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

AUG 29 2002

Page 1 of 1

TECH CENTER 1600/2900

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/073,644	02/11/2002	Debra Hudson	MXI-211

CONFIRMATION NO. 6293

000959
LAHIVE & COCKFIELD
28 STATE STREET
BOSTON, MA 02109

FORMALITIES LETTER

DOCKETED

COPY

Sept 30, 2002 - SEQUENCE LISTING BUE

Sept 29, 2002 - E.S.P. W/S MOX.

Date Mailed: 07/30/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY

RECEIVED LAHIVE & COCKFIELD DOCKET DEPT.
AUG - 15 2002
RETRIEVED FORWARDED

COPY OF PAPERS
ORIGINALLY FILED

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Date: August 9, 2002

Signature

Jeanne M. DiGiorgio
Jeanne M. DiGiorgio

Docket No.: MXI-211
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Debra Hudson, et al.

Application No.: 10/073644

Group Art Unit: 1636

Filed: February 11, 2002

Examiner: Not Yet Assigned

For: HUMAN MONOCLONAL ANTIBODIES TO FC
ALPHA RECEPTOR (CD89)

RECEIVED

AUG 29 2002

TECH CENTER 1600/2900

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents
Washington, DC 20231

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, Applicants respectfully submit another copy of the Sequence Listing Diskette to replace the Sequence Listing Diskette which was filed on February 11, 2002 and subsequently damaged. No new matter has been added.

Please charge any necessary fees to our Deposit Account No. 12-0080. A duplicate copy of this paper is enclosed.

Dated: August 20, 2002

Respectfully submitted,

By *Jeanne M. DiGiorgio*
Jeanne M. DiGiorgio
Registration No.: 41,740
LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
(617) 227-7400
(617) 742-4214 (Fax)
Attorneys for Applicant

COPY OF PAPERS
ORIGINALLY FILED

1636

Please type a plus sign inside this box

+

3 TRANS

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTOSB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/073644
		Filing Date	February 11, 2002
		First Named Inventor	Debra Hudson
		Group Art Unit	1636
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission		Attorney Docket Number	MXI-211

RECEIVE

AUG 29 2002

TECH CENTER 1600/2

ENCLOSURES (check all that apply)

<input type="checkbox"/> File Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/Deliberation(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input checked="" type="checkbox"/> Return Receipt Postcard
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	1. Response to Notice to Comply with Requirements for Patent Applications Containing Accelerated Sequence under AIA/AIA Sequence Disclosure;
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	2. Copy of Notice to Comply with Requirements for Patent Applications Containing Accelerated Sequence under AIA/AIA Sequence Disclosure;
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Diskette	3. Sequence Listing and
		4. Statement pursuant to 37 CFR 1.824(f)
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

Please charge any necessary fees to our Deposit Account No. 12-0080. The undersigned requests any extensions of time necessary to respond. A duplicate of this sheet is enclosed.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual Name	LAHIVE & COCKFIELD, LLP Jeanne M. DiGiorgio - 41,710
Signature	
Date	August 20, 2002

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: August 20, 2002

Signature:

(Jeanne M. DiGiorgio)